David Berz

1.8k total citations
75 papers, 932 citations indexed

About

David Berz is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, David Berz has authored 75 papers receiving a total of 932 indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Oncology, 33 papers in Pulmonary and Respiratory Medicine and 18 papers in Molecular Biology. Recurrent topics in David Berz's work include Lung Cancer Treatments and Mutations (23 papers), HER2/EGFR in Cancer Research (14 papers) and Cancer Immunotherapy and Biomarkers (10 papers). David Berz is often cited by papers focused on Lung Cancer Treatments and Mutations (23 papers), HER2/EGFR in Cancer Research (14 papers) and Cancer Immunotherapy and Biomarkers (10 papers). David Berz collaborates with scholars based in United States, Germany and Japan. David Berz's co-authors include Gerald A. Colvin, Peter J. Quesenberry, Eric S. Winer, Elise McCormack, Mark S. Dooner, Harold J. Wanebo, Bharat Ramratnam, Douglas C. Hixson, Jason M. Aliotta and David Lee and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

David Berz

69 papers receiving 899 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Berz United States	16	382	269	216	182	157	75	932
Jie Ding China	16	604 1.6×	205 0.8×	178 0.8×	160 0.9×	115 0.7×	57	1.2k
Lionel D’Hondt Belgium	19	363 1.0×	309 1.1×	340 1.6×	177 1.0×	147 0.9×	65	1.1k
Hyeon Seok Eom South Korea	15	392 1.0×	590 2.2×	96 0.4×	136 0.7×	153 1.0×	58	1.3k
Xiaorui Fu China	19	360 0.9×	605 2.2×	129 0.6×	224 1.2×	84 0.5×	91	1.2k
Qingfang Li China	17	437 1.1×	336 1.2×	222 1.0×	235 1.3×	55 0.4×	37	1.0k
Preston D. Steen United States	18	259 0.7×	579 2.2×	329 1.5×	129 0.7×	79 0.5×	47	1.0k
Clara Klerk Netherlands	9	245 0.6×	196 0.7×	134 0.6×	102 0.6×	279 1.8×	18	1.1k
Masafumi Takimoto Japan	13	213 0.6×	402 1.5×	171 0.8×	67 0.4×	99 0.6×	40	815
H. J. Illiger Germany	11	386 1.0×	555 2.1×	266 1.2×	154 0.8×	172 1.1×	28	974

Countries citing papers authored by David Berz

Since Specialization

Citations

This map shows the geographic impact of David Berz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Berz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Berz more than expected).

Fields of papers citing papers by David Berz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Berz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Berz. The network helps show where David Berz may publish in the future.

Co-authorship network of co-authors of David Berz

This figure shows the co-authorship network connecting the top 25 collaborators of David Berz. A scholar is included among the top collaborators of David Berz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Berz. David Berz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Spira, Alexander I., et al.. (2025). Dose Escalation Trial of the Combination of Osimertinib and Quaratusugene Ozeplasmid Gene Therapy in Patients with Advanced NSCLC. Clinical Lung Cancer. 27(1). 75–81.

Heymach, John V., Frans L. Opdam, Minal Barve, et al.. (2025). HER2-Selective Tyrosine Kinase Inhibitor, Zongertinib (BI 1810631), in Patients With Advanced/Metastatic Solid Tumors With HER2 Alterations: A Phase Ia Dose-Escalation Study. Journal of Clinical Oncology. 43(11). 1337–1347. 10 indexed citations

Hurvitz, Sara A., Matteo Simonelli, Ramón Yarza, et al.. (2025). Beamion BCGC-1: phase Ib/II trial of zongertinib for advanced HER2-positive breast or gastroesophageal cancers. Future Oncology. 21(26). 3385–3393.

Nakayama, Izuma, et al.. (2025). Beamion BCGC-1: A phase Ib/II trial of the HER2-selective tyrosine kinase inhibitor (TKI) zongertinib (BI 1810631) + trastuzumab deruxtecan (T-DXd) or trastuzumab emtansine (T-DM1) for patients with metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC).. Journal of Clinical Oncology. 43(4_suppl). 3 indexed citations

Harrington, Kevin J., et al.. (2024). 1007P Systemic STING agonist BI 1703880 plus ezabenlimab in patients (pts) with advanced solid tumors: Initial results from a phase Ia study. Annals of Oncology. 35. S684–S685. 2 indexed citations

Berz, David, John V. Heymach, Frans L. Opdam, et al.. (2024). Beamion LUNG-1, a Phase Ia/Ib trial of the HER2-specific tyrosine kinase inhibitor, zongertinib (BI 1810631), in patients with HER2-driven tumors: outcomes according to HER2 aberration type. American Journal of Clinical Pathology. 162(Supplement_1). S127–S127. 1 indexed citations

Opdam, Frans L., John V. Heymach, David Berz, et al.. (2024). MA12.10 Zongertinib (BI 1810631) For HER2-Positive Solid Tumors with Brain Metastases: Subanalysis of the Beamion LUNG-1 Trial. Journal of Thoracic Oncology. 19(10). S105–S105. 2 indexed citations

Heymach, John V., Noboru Yamamoto, Frans L. Opdam, et al.. (2024). OA01.01 Beamion LUNG-1: Phase Ia/b Trial of HER2 Tyrosine Kinase Inhibitor Zongertinib (BI 1810631) in Patients with HER2 Aberration-Positive Solid Tumors. Journal of Thoracic Oncology. 19(7). e1–e1.

Park, Jong Chul, David Berz, Manish Sharma, et al.. (2023). 742 Phase 1/2 study of the bispecific 4–1BB and PD-L1 antibody INBRX-105 alone and in combination with pembrolizumab in select solid tumors. SHILAP Revista de lepidopterología. A836–A837. 2 indexed citations

10.

Subbiah, Vivek, Sant P. Chawla, Anthony P. Conley, et al.. (2023). Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma. Clinical Cancer Research. 29(16). 2988–3003. 28 indexed citations

11.

He, Kai, David Berz, Shirish M. Gadgeel, et al.. (2023). MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy. Journal of Thoracic Oncology. 18(7). 907–921. 20 indexed citations

12.

Leal, Ticiana, David Berz, Igor I. Rybkin, et al.. (2022). 43P MRTX-500: Phase II trial of sitravatinib (sitra) + nivolumab (nivo) in patients (pts) with non-squamous (NSQ) non-small cell lung cancer (NSCLC) progressing on or after prior checkpoint inhibitor (CPI) therapy. Annals of Oncology. 33. S19–S20. 13 indexed citations

13.

Spigel, David R., Robert M. Jotte, John Nemunaitis, et al.. (2020). Randomized Phase 2 Studies of Checkpoint Inhibitors Alone or in Combination With Pegilodecakin in Patients With Metastatic NSCLC (CYPRESS 1 and CYPRESS 2). Journal of Thoracic Oncology. 16(2). 327–333. 36 indexed citations

14.

Spira, Alexander I., Collin M. Blakely, Kai He, et al.. (2018). Stage 2 enrollment complete: Sitravatinib in combination with nivolumab in NSCLC patients progressing on prior checkpoint inhibitor therapy. Annals of Oncology. 29. viii400–viii401. 9 indexed citations

15.

Singhal, Sharad S., James L. Figarola, Jyotsana Singhal, et al.. (2013). RLIP76 Protein Knockdown Attenuates Obesity Due to a High-fat Diet. Journal of Biological Chemistry. 288(32). 23394–23406. 21 indexed citations

16.

Berz, David & Harold J. Wanebo. (2011). Targeting the growth factors and angiogenesis pathways: Small molecules in solid tumors. Journal of Surgical Oncology. 103(6). 574–586. 19 indexed citations

17.

Tatto, Michael Del, Thomas Ng, Jason M. Aliotta, et al.. (2011). Marrow cell genetic phenotype change induced by human lung cancer cells. Experimental Hematology. 39(11). 1072–1080. 20 indexed citations

18.

Colvin, Gerald A., David Berz, Muthalagu Ramanathan, et al.. (2009). Nonengraftment Haploidentical Cellular Immunotherapy for Refractory Malignancies: Tumor Responses without Chimerism. Biology of Blood and Marrow Transplantation. 15(4). 421–431. 56 indexed citations

19.

Milani, Cannon, Maria Constantinou, David Berz, James N. Butera, & Gerald A. Colvin. (2008). Left sided inferior vena cava duplication and venous thromboembolism: case report and review of literature. Journal of Hematology & Oncology. 1(1). 24–24. 43 indexed citations

20.

Berz, David, Elise McCormack, Eric S. Winer, Gerald A. Colvin, & Peter J. Quesenberry. (2007). Cryopreservation of hematopoietic stem cells. American Journal of Hematology. 82(6). 463–472. 179 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact